DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 114 filers reported holding DYNE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.06 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,512,952 | -40.2% | 1,508,142 | -25.0% | 0.00% | -40.0% |
| Q2 2023 | $22,607,202 | +31.3% | 2,009,529 | +34.5% | 0.01% | +25.0% |
| Q1 2023 | $17,216,064 | +77.7% | 1,494,450 | +78.8% | 0.00% | +100.0% |
| Q4 2022 | $9,689,437 | +91.9% | 836,017 | +110.3% | 0.00% | +100.0% |
| Q3 2022 | $5,049,000 | +1012.1% | 397,570 | +502.0% | 0.00% | – |
| Q2 2022 | $454,000 | -40.0% | 66,043 | -15.9% | 0.00% | – |
| Q1 2022 | $757,000 | -24.8% | 78,557 | -7.2% | 0.00% | – |
| Q4 2021 | $1,006,000 | +57.9% | 84,618 | +115.5% | 0.00% | – |
| Q3 2021 | $637,000 | -83.4% | 39,269 | -78.4% | 0.00% | -100.0% |
| Q2 2021 | $3,833,000 | +140.8% | 182,146 | +77.7% | 0.00% | – |
| Q1 2021 | $1,592,000 | +69.5% | 102,513 | +129.2% | 0.00% | – |
| Q4 2020 | $939,000 | -73.9% | 44,719 | -74.9% | 0.00% | -100.0% |
| Q3 2020 | $3,594,000 | – | 177,987 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,960,046 | $35,195,000 | 13.16% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $58,871,000 | 12.72% |
| Atlas Venture Life Science Advisors, LLC | 8,934,902 | $106,236,000 | 9.76% |
| Logos Global Management LP | 3,234,392 | $38,457,000 | 3.97% |
| GREAT POINT PARTNERS LLC | 845,000 | $10,047,000 | 2.23% |
| Deep Track Capital, LP | 2,292,250 | $27,255,000 | 1.92% |
| Octagon Capital Advisors LP | 583,649 | $6,940,000 | 1.35% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 476,000 | $5,641,000 | 1.26% |
| COMMODORE CAPITAL LP | 305,125 | $3,628,000 | 0.84% |
| RA Capital Management | 2,805,045 | $33,352,000 | 0.59% |